Tag: paratek pharmaceuticals

5 Top Weekly NASDAQ Biotech and Pharma Stocks: Paratek Up 41 Percent

Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...

Paratek’s Phase 3 Studies of NUZYRA Published in Medical Journal

Wednesday's announcement comes after the company revealed on Tuesday that NUZYRA is now commercially available in the US.

Biotech Update: Q3 2018 in Review

With the first three quarters of 2018 over, the Investing News Network is reviewing top news in the biotech space...

5 Top Weekly NASDAQ Biotech Stocks: vTv Leads with 374 Percent

vTv Therapeutics, Trevena, Cyclacel Pharmaceuticals, Paratek Pharmaceuticals and Avadel Pharmaceuticals were last week's top gainers on the NASDAQ Biotechnology Index.

FDA Approves SEYSARA (Sarecycline) for the Treatment of Moderate to Severe Acne

Paratek Pharmaceuticals (Nasdaq:PRTK) a biopharmaceutical company focused on the development and commercialization of therapies based upon tetracycline chemistry, today announced...

FDA Recommends Approval for Paratek’s Omadacycline

On Thursday, the US FDA's Antimicrobials Drug Advisory Committee voted in favor of approvals for two of Paratek Pharmaceuticals' drugs.

FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline

Paratek Pharmaceuticals (NASDAQ:PRTK) today announced that the Antimicrobials Drug Advisory Committee of the U.S. Food and Drug Administration voted in...